艾多沙班与利伐沙班能否用于哺乳期母亲?新视野临床试验
这项4期药代动力学试验在产后12周内志愿者中评估利伐沙班和艾多沙班的母体及乳汁药代动力学。4名哺乳期女性分别服用利伐沙班20mg每日或艾多沙班60mg每日共3天。利伐沙班入乳浓度低(乳汁AUC 583 ng/mL.h,M:P比0.2),艾多沙班入乳与母体血浆浓度相近(乳汁AUC 1654 ng/mL.h,M:P比0.9)。PBPK模拟显示两药在完全母乳喂养婴儿中血浆浓度低。
要点
- 利伐沙班入乳浓度低,乳汁AUC为583 ng/mL.h,M:P比0.2。
- 艾多沙班入乳浓度较高,乳汁AUC为1654 ng/mL.h,M:P比0.9。
- PBPK模拟显示两药在完全母乳喂养婴儿中血浆浓度低。
核心结论
- 从喂养婴儿安全性角度,研究结果为哺乳期女性使用利伐沙班提供了有力证据。
- 艾多沙班在哺乳期女性中的使用值得进一步研究。
- 可考虑开展利伐沙班对比低分子肝素的产后血栓预防试验以确立母体疗效和安全性。
研究设计与样本
- 4期药代动力学临床试验,纳入产后12周内志愿哺乳期女性。
- 2名服用利伐沙班20 mg每日,2名服用艾多沙班60 mg每日,连续3天。
- 匹配采集母体血浆和母乳样本共6天,进行非房室药代动力学分析及基于生理的药代动力学分析。
主要发现
- 利伐沙班以低浓度分布入人乳汁,第3天稳态乳汁AUC均值为583 ng/mL.h,乳汁:血浆比值为0.2。
- 艾多沙班分布入人乳汁与母体血浆浓度相近,第3天稳态乳汁AUC均值为1654 ng/mL.h,乳汁:血浆比值为0.9。
- 两药的PBPK模拟显示完全母乳喂养婴儿血浆浓度低。
临床怎么用
- 从喂养婴儿安全性角度,可考虑在哺乳期女性中使用利伐沙班。
- 艾多沙班在哺乳期女性中的使用需进一步研究后再决策。
局限性
- 样本量小,仅4名女性参与(利伐沙班2名,艾多沙班2名)。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The risk of venous thromboembolism is significantly increased during the postnatal period, and pharmacological thromboprophylaxis remains the cornerstone of venous thromboembolism preventive measures. It is well recognized that many women struggle with the parenteral nature of low-molecular-weight heparin. OBJECTIVES: The aim of this phase 4 pharmacokinetic clinical trial was to characterize the maternal and breastmilk pharmacokinetics of rivaroxaban and edoxaban at steady state in volunteer women within 12 weeks of delivery. METHODS: Volunteer breastfeeding women were recruited and, following informed written consent, took rivaroxaban 20 mg daily or edoxaban 60 mg daily for 3 consecutive days, with matched maternal plasma and breastmilk samples obtained over 6 days. Noncompartmental pharmacokinetic analysis was conducted, including computation of the milk:plasma ratio at steady state. Additionally, physiologically based pharmacokinetic analysis was conducted, allowing simulation of expected feeding-infant plasma concentrations following maternal ingestion. ISRCTN registry: ISRCTN5783139. RESULTS: Four women took part, with 2 taking edoxaban and 2 taking rivaroxaban. Rivaroxaban distributed into human breastmilk at low concentrations; the mean breastmilk area under the concentration-time curve at steady state on day 3 was 583 ng/mL.h, and the milk:plasma ratio 0.2. Edoxaban distributed into human breastmilk mirrored the maternal plasma concentration; the mean breastmilk area under the concentration-time curve at steady state on day 3 was 1654 ng/mL.h, and the milk:plasma ratio was 0.9. Physiologically based pharmacokinetic simulations for both drugs show low infant plasma concentrations in fully breastfed infants. CONCLUSION: Our findings provide compelling evidence for using rivaroxaban in breastfeeding women from a feeding-infant's safety perspective. Testing rivaroxaban against low-molecular-weight heparin in a postnatal thromboprophylaxis trial should be considered to establish maternal efficacy and safety. Edoxaban use in breastfeeding women merits further investigation.
引用
- Patel JP, Butler AS, Mackina G, et al. Can edoxaban and rivaroxaban be prescribed for breastfeeding mothers? The New Horizons clinical trial. J Thromb Haemost. 2026. PMID: 42480855. doi:10.1016/j.jtha.2026.07.010
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。